- Home
- RGC vs IVZ Comparison
RGC vs IVZ Comparison
Compare RGC & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGC | IVZ |
|---|---|---|
| Founded | 2014 | 1935 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RGC | IVZ |
|---|---|---|
| Price | $29.30 | $25.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $27.43 |
| AVG Volume (30 Days) | 100.6K | ★ 5.8M |
| Earning Date | 10-31-2025 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,314,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.98 |
| 52 Week Low | $9.39 | $14.04 |
| 52 Week High | $950.00 | $29.61 |
Technical Indicators
Market Signals| Indicator | RGC | IVZ |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 59.16 |
| Support Level | $21.81 | $25.12 |
| Resistance Level | $33.50 | $27.46 |
| Average True Range (ATR) | 2.01 | 0.79 |
| MACD | -0.10 | 0.16 |
| Stochastic Oscillator | 39.91 | 80.36 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).